Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22615346 | 0.98 | HCAR2 (0.59) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL16127970 | 0.86 | HCAR2 (0.61) | HCAR2KMT2ATSHRRBP4 | |
| SCHEMBL14520684 | 0.84 | HCAR2 (0.42) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL4761168 | 0.84 | HCAR2 (0.42) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL4946106 | 0.83 | HCAR2 (0.56) | HCAR2KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL30587571 | 0.83 | HCAR2 (0.41) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL4762236 | 0.80 | GAA (0.41) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL17870524 | 0.79 | RBP4 (0.39) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL17870536 | 0.78 | RBP4 (0.38) | HCAR2KMT2ATSHRSOS1RBP4 | |
| SCHEMBL17868694 | 0.77 | SOS1 (0.45) | HCAR2KMT2ASOS1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031701-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH UNCONTROLLED INFLAMMATORY RESPONSES | SYNKRINO BIOTHERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11147815-B2 | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses | SYNKRINO BIOTHERAPEUTICS, INC. | 2021-10-19 | — | — | US | disclosed |
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| EP-1804791-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006049880-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | HCAR2 1517/4885KMT2A 4148/4885TSHR 3754/4885 |
| US-11147815-B2 | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses | TRIM28, TRIM58, CD14 | HCAR2 1509/4885KMT2A 1312/4885TSHR 4389/4885 |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HCAR2 1517/4885KMT2A 4148/4885TSHR 3754/4885 |
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | HCAR2 1517/4885KMT2A 4148/4885TSHR 3754/4885 |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | HCAR2 183/4885KMT2A 2839/4885TSHR 1297/4885 |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HCAR2 1517/4885KMT2A 4148/4885TSHR 3754/4885 |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HCAR2 1517/4885KMT2A 4148/4885TSHR 3754/4885 |
| US-20220031701-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH UNCONTROLLED INFLAMMATORY RESPONSES | TRIM28, TRIM58, CD14 | HCAR2 1509/4885KMT2A 1312/4885TSHR 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.